Get the Stockscreener App
61.68
3.44%
+2.05
After Hours:
61.68
RxSight Inc stock is currently priced at $61.68, with a 24-hour trading volume of 531.63K.
It has seen a +3.44% increased in the last 24 hours and a +20.37% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $58.81 pivot point. If it approaches the $63.11 resistance level, significant changes may occur.
Previous Close:
$59.63
Open:
$60
24h Volume:
531.63K
Market Cap:
$2.29B
Revenue:
$89.08M
Net Income/Loss:
$-48.61M
P/E Ratio:
-30.99
EPS:
-1.99
Net Cash Flow:
$-46.41M
1W Performance:
+16.88%
1M Performance:
+20.37%
6M Performance:
+155.19%
1Y Performance:
+227.21%
1D Range:
$59.59
$61.85
52W Range:
$18.09
$61.85
RxSight Inc Stock (RXST) Company Profile
Name
RxSight Inc
Sector
Industry
Phone
949-521-7830
Address
100 Columbia, Suite 120, Aliso Viejo
RxSight Inc Stock (RXST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-23 | Initiated | Stifel | Buy |
| Dec-04-23 | Initiated | Morgan Stanley | Overweight |
| Apr-13-23 | Initiated | Oppenheimer | Outperform |
| Dec-12-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-08-22 | Initiated | Needham | Buy |
View All
RxSight Inc Stock (RXST) Latest News
RxSight, Inc. to Report First Quarter Financial Results on May 6, 2024
GlobeNewswire Inc.
Assessing RxSight: Insights From 8 Financial Analysts
Benzinga
RxSight Announces Commercial Launch of its Newest Light Adjustable Lens™, the LAL+™, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting
GlobeNewswire Inc.
RxSight, Inc. to Participate in the 23rd Annual Needham Virtual Healthcare Conference
GlobeNewswire Inc.
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
Zacks Investment Research
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
Zacks Investment Research
RxSight Inc Stock (RXST) Financials Data
RxSight Inc (RXST) Revenue 2024
RXST reported a revenue (TTM) of $89.08 million for the quarter ending December 31, 2023, a +81.77% rise year-over-year.
RxSight Inc (RXST) Net Income 2024
RXST net income (TTM) was -$48.61 million for the quarter ending December 31, 2023, a +27.19% increase year-over-year.
RxSight Inc (RXST) Cash Flow 2024
RXST recorded a free cash flow (TTM) of -$46.41 million for the quarter ending December 31, 2023, a +24.22% increase year-over-year.
RxSight Inc (RXST) Earnings per Share 2024
RXST earnings per share (TTM) was -$1.42 for the quarter ending December 31, 2023, a +41.32% growth year-over-year.
About RxSight Inc
RxSight, Inc., a medical technology company, develops light adjustable lens (LAL) to improve uncorrected visual acuity that can be adjusted enhance uncorrected visual acuity after cataract surgery. It also offers RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is based in Aliso Viejo, California.
0.77%
Cap:
|
Volume (24h):